![]() In this paper, we proposed a new group sequential test procedure fully accounting for both seasonality and variation from the historical controls. Furthermore, not rejecting the null could be due to a lack of power and cannot always be interpreted as proof of safety. ![]() Such an approach doesn't account for either the variation in determining the reference risk from a control population or the seasonality effect. If the null hypothesis is never rejected, the vaccine is considered safe. When the number of AEs is "too high", a safety signal is identified. Specifically, it compares the post-vaccination incidence of adverse event (AE) in a vaccinated population with a pre-specified reference level by sequentially conducting hypothesis testing during the surveillance. The group sequential analysis is a common method employed in safety surveillance. Post-market active safety monitoring is important for the timely capture of safety signals associated with exposure to a new vaccine or drug. Vice Provost for Undergraduate Education.Office of Vice President for Business Affairs and Chief Financial Officer.Office of VP for University Human Resources.Stanford Woods Institute for the Environment.Stanford Institute for Economic Policy Research (SIEPR).Institute for Stem Cell Biology and Regenerative Medicine.Institute for Human-Centered Artificial Intelligence (HAI).Institute for Computational and Mathematical Engineering (ICME).Freeman Spogli Institute for International Studies.Stanford Doerr School of Sustainability.This will overcome many challenging situations currently faced in clinical medicine such as organ scarring and the lack of donor organs. What medical discovery are you hoping will be achieved in your lifetime?Įventually, I hope there will be a new discoveries that leads to potential therapies by altering both the immune system and the adult stem cell populations to promote complete organ regeneration. These will potentially reveal the mechanisms that determine incomplete tissue repair (scarring) and complete regeneration. In particular, I would like to investigate whether T regulatory cells, a special cell type that is well known for controlling the immune response, can affect the fate of liver stem cells and how this is achieved. I hope I can establish my research group here in Birmingham with the focus on studying the role of adaptive immune response in promoting liver regeneration. What are you hoping to accomplish while in Birmingham? Furthermore, the attractive Birmingham Fellowship Scheme provides me the opportunity to join the University with abundant support to setup my independent research career. ![]() The strong link between the Centre for Liver and Gastrointestinal Research and the Institute of Immunology and Immunotherapy is the perfect environment to pursue my research interest which covers both immunology and liver regeneration. The University of Birmingham has a longstanding excellence in liver research. What attracted you to the University of Birmingham? During my time in Edinburgh, I have identified an adult liver progenitor cell population and shown the potential of using adult progenitor cells for future therapies. My previous research focused on studying the role of liver stem cell and regeneration. I was based at the Scottish Centre for Regenerative Medicine at the University of Edinburgh. Dr Wei-Yu Lu Birmingham Fellow | Institute of Immunology and Immunotherapy ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |